A medium-chain acyl-CoA dehydrogenase deficiency genetic test analyzes ACADM, the gene responsible for MCAD deficiency. This inherited fatty acid oxidation disorder limits the body’s ability to use medium-chain fats for energy when food intake stops and stored glucose becomes depleted. Most affected newborns appear healthy, but fasting, fever, vomiting, surgery, or prolonged exercise can trigger hypoketotic hypoglycemia, liver dysfunction, seizures, coma, or sudden death. Newborn screening commonly detects an elevated C8 acylcarnitine pattern before symptoms begin. Genetic testing then helps confirm the cause, identify the two disease-causing variants, test relatives, and clarify reproductive risk. A molecular diagnosis usually requires pathogenic or likely pathogenic variants in both ACADM copies. One variant generally indicates carrier status. During suspected metabolic illness, however, emergency glucose treatment and biochemical assessment must not wait for the genetic report.
- MCAD deficiency is usually confirmed by two pathogenic or likely pathogenic ACADM variants plus compatible biochemical findings.
- Newborn screening detects an acylcarnitine pattern, not the gene itself, and requires prompt confirmation.
- The common ACADM c.985A>G variant explains many cases in some European-ancestry populations but is not the only cause.
- One pathogenic variant usually means carrier status; two variants should be shown or expected to be on opposite chromosome copies.
- A negative result does not override a strongly abnormal C8 acylcarnitine and urine organic acid profile.
- Avoiding fasting and following a written illness plan can prevent most serious metabolic crises.
Table of Contents
- What MCAD Deficiency Does to Energy Metabolism
- Newborn Screening and Diagnostic Confirmation
- ACADM Genetic Test Methods
- Interpreting Positive, Carrier, Negative, and VUS Results
- Daily Management and Fasting Prevention
- Illness, Surgery, and Emergency Care
- Family Testing and Reproductive Risk
- Questions for the Care Team
What MCAD Deficiency Does to Energy Metabolism
The body normally shifts between glucose and fat as fuel. During an overnight fast, infection, vomiting illness, or other period of reduced intake, the liver breaks down fatty acids to generate energy and ketones. The medium-chain acyl-CoA dehydrogenase enzyme performs an early step in mitochondrial beta-oxidation of medium-chain fatty acids.
When ACADM activity is severely reduced, this backup energy pathway fails. Glucose stores can fall rapidly, while ketone production is lower than expected for the degree of hypoglycemia. Medium-chain fatty acid metabolites accumulate and may affect the liver and brain.
Typical metabolic crisis
An infant or child may become ill after a seemingly ordinary viral infection or a longer-than-usual fast. Early signs can include poor feeding, repeated vomiting, unusual sleepiness, irritability, weakness, or reduced responsiveness. Progression may include hypoglycemia, seizures, breathing abnormalities, coma, liver enlargement, or sudden death.
Hypoglycemia is an important finding, but it may appear late. A known patient with poor intake and lethargy needs urgent treatment even before a low glucose value is documented. The absence of strong urine ketones is not reassuring because inadequate ketone production is part of the disorder.
Why newborns can look normal
A baby with MCAD deficiency can have normal growth and examination between metabolic stresses. Symptoms do not arise from a fixed lack of energy every day; they occur when the body needs fat oxidation to maintain fuel. This explains why prevention is so effective once the diagnosis is known and why the first unrecognized crisis can be catastrophic.
Some individuals first present in later childhood or adulthood after prolonged fasting, surgery, heavy alcohol use, extreme dieting, or endurance exercise. A normal childhood history does not exclude ACADM-related disease.
Genotype and severity
The common c.985A>G variant, which produces p.Lys329Glu under current nomenclature, is associated with marked enzyme deficiency when present on both alleles. Older reports may call the same protein change K304E because of historical numbering. Other ACADM variants can produce a spectrum of residual activity and biochemical findings.
A milder newborn-screening profile does not guarantee that fasting is safe. Genotype, enzyme function, acylcarnitines, and clinical history may help a metabolic specialist individualize care, but all confirmed patients need a prevention plan.
Newborn Screening and Diagnostic Confirmation
Expanded newborn screening usually identifies MCAD deficiency by tandem mass spectrometry on a dried blood spot. The characteristic marker is elevated octanoylcarnitine, or C8, often interpreted with C6, C10, and ratios such as C8/C10. Screening programs use their own cutoffs and algorithms.
A positive screen is not yet a diagnosis. It is an urgent signal to contact the family, assess the baby, prevent fasting, and obtain confirmatory testing. The infant may be entirely well when the call is made.
Confirmatory biochemical tests
Plasma acylcarnitine analysis can confirm a persistent C8-predominant pattern. Urine organic acid or acylglycine testing may show hexanoylglycine, suberylglycine, and other medium-chain metabolites. Free and total carnitine, blood glucose, liver tests, ammonia, and other studies may be obtained depending on the infant’s condition.
Results can be less pronounced when the child is well, has already received glucose, or has low carnitine. Conversely, some non-MCAD conditions, medications, nutrition products, or specimen factors can produce an abnormal screening pattern. Biochemistry and molecular testing should be interpreted together.
Genetic confirmation
Finding two pathogenic or likely pathogenic variants in ACADM confirms the molecular diagnosis in a person with compatible biochemical findings. Genetic testing can distinguish true disease from some false-positive screens, establish the exact familial variants, and make carrier or prenatal testing possible.
The diagnostic process belongs within the broader newborn screening follow-up system. A family should receive direct instructions from a metabolic center rather than waiting for a routine pediatric appointment.
A normal newborn screen does not exclude every case
Screening sensitivity is high but not absolute. Specimen timing, transfusion, nutrition, carnitine status, laboratory cutoffs, and variants associated with less pronounced metabolite elevations may affect detection. An older child or adult with unexplained hypoketotic hypoglycemia, liver dysfunction during fasting, or a sibling with MCAD deficiency may still need biochemical and ACADM testing despite a reported normal newborn screen.
ACADM Genetic Test Methods
Clinical testing usually starts with sequencing of ACADM coding exons and nearby splice regions. A complete assay should also evaluate exon-level deletions and duplications, because routine sequence analysis may not identify larger copy-number changes.
Comprehensive testing versus common-variant testing
Targeted analysis for c.985A>G can be useful when confirming a known family variant or as part of a rapid founder-focused strategy. It is not a complete diagnostic test. Many affected people have a different variant on one or both alleles, particularly outside populations in which c.985A>G is common.
After an abnormal newborn screen, comprehensive ACADM sequencing with deletion/duplication analysis is generally more informative than testing only c.985A>G. The report should specify transcript, nucleotide and protein nomenclature, zygosity, classification, and assay limitations.
Panel, exome, and genome approaches
A fatty acid oxidation or hypoglycemia panel may be appropriate when the biochemical pattern is not specific. Other disorders—including very-long-chain acyl-CoA dehydrogenase deficiency, multiple acyl-CoA dehydrogenase deficiency, carnitine transport defects, ketogenesis disorders, and endocrine causes—can overlap clinically.
Exome or genome sequencing may be used in unresolved cases, but negative genomic testing does not replace metabolic studies. Coverage of ACADM exons, copy-number sensitivity, intronic regions, and mitochondrial or biochemical differential diagnoses must be reviewed explicitly.
Establishing phase
When two different variants are reported, parental testing can show whether they are in trans, one on each chromosome copy. If both variants are in cis on the same copy, the individual may have only one affected allele and a second cause must be sought.
Phase may sometimes be inferred from prior family data or sequencing technology, but the report should state whether it is known. Parental testing also clarifies carrier status and helps detect rare events such as a de novo variant, uniparental disomy, or parental mosaicism.
Biochemical testing is not carrier testing
Carriers typically have enough enzyme activity to remain healthy and may have normal acylcarnitines. Plasma or urine metabolite testing is therefore not a reliable method for identifying relatives who carry one familial variant. Molecular testing is preferred.
Interpreting Positive, Carrier, Negative, and VUS Results
The meaning of an ACADM result depends on the number of variants, their classification, their phase, and the biochemical phenotype.
Two pathogenic or likely pathogenic variants
Two disease-causing variants in trans establish biallelic ACADM deficiency. The person is affected even if asymptomatic at the time of testing. Newborn-screened patients may never experience a crisis if fasting is prevented, but the underlying metabolic vulnerability remains.
The report may describe the variants as homozygous when the same change is present on both copies, or compound heterozygous when two different changes are present. A molecular diagnosis supports a permanent emergency plan, family testing, and reproductive counseling.
Genotype can sometimes correlate with residual enzyme activity, but it should not be used alone to withdraw precautions. Clinical protocols may evolve as outcome data for milder variants improve.
One pathogenic variant
In a healthy relative, one pathogenic ACADM variant means carrier status. Carriers are not expected to develop MCAD deficiency and do not need fasting restrictions or an emergency glucose plan.
In a newborn or symptomatic patient with a convincing biochemical profile, finding one variant leaves the diagnosis incomplete rather than disproved. The second variant may be a deletion, deep intronic change, structural rearrangement, or variant missed by the initial method. The laboratory and metabolic team may add copy-number analysis, RNA testing, genome sequencing, enzyme studies, or reanalysis.
Pathogenic variant plus a VUS
A pathogenic variant paired with a variant of uncertain significance may or may not explain the disorder. Strong C8 and urine metabolite evidence can support ongoing clinical treatment while the molecular result remains unresolved, but the VUS itself should not be called disease-causing without sufficient evidence.
Phase, segregation, population frequency, functional studies, computational evidence, and observations in other patients may help reclassification. A VUS should not be used alone for predictive testing of healthy relatives or embryo selection. The distinction between clinical precaution and molecular certainty should be documented.
Negative result
A negative ACADM test means no reportable variant was found with the assay. It lowers the likelihood of MCAD deficiency but does not overrule a strongly characteristic biochemical profile. The report should be checked for deletion/duplication analysis, coverage gaps, and excluded variant classes.
A negative result after a borderline newborn screen may support a false-positive interpretation when repeat biochemical testing is also normal. That conclusion should come from a metabolic specialist, not from the genetic report alone.
A negative targeted test is more definitive when the family’s two variants are known. A sibling who tests negative for both familial variants is not affected and is not a carrier of either identified variant.
Benign variants and older terminology
Benign and likely benign variants do not cause MCAD deficiency and should not drive management. Older reports may use “mutation,” “polymorphism,” or legacy protein numbering. A current laboratory or genetics professional can map the old notation to modern ACADM nomenclature before relatives are tested.
Daily Management and Fasting Prevention
The central treatment is preventing prolonged fasting. The safe interval without food depends on age, health, overnight tolerance, and the metabolic center’s protocol. Infants require frequent feeding; fasting tolerance generally increases with age, but illness can shorten it again.
Routine diet
Most well individuals do not need severe fat or protein restriction. A balanced diet with regular meals and adequate complex carbohydrate is typical. Infants may use standard breast milk or formula unless the metabolic team advises otherwise.
Medium-chain triglyceride supplements, concentrated coconut or MCT products, and ketogenic diets can provide substrates that an MCAD-deficient person cannot process normally. They should not be used without specialist approval. Weight-loss plans involving fasting, very-low-carbohydrate intake, or prolonged meal skipping can also be hazardous.
Carnitine supplementation is not automatically required for every patient. It may be considered when free carnitine is persistently low, but evidence and practice vary. Dose and monitoring belong with the metabolic team.
Overnight and activity planning
Young children may need scheduled bedtime snacks or limited overnight fasting. Some patients use uncooked cornstarch under specialist guidance, but this is not universal. Feeding schedules should be updated as the child grows rather than copied indefinitely from an infant plan.
Ordinary physical activity is beneficial. Prolonged endurance exercise, heat, inadequate carbohydrate intake, or exercising while ill can increase risk. Planning may include pre-exercise carbohydrate, hydration, and limits tailored to the individual.
Alcohol and adult risks
Heavy alcohol intake can suppress glucose production and extend fasting, creating a dangerous combination. Adults should discuss alcohol, shift work, religious fasting, travel, pregnancy, and weight-management goals with their metabolic clinician.
Medical identification jewelry or a phone emergency card can alert clinicians that dextrose may be needed even when ketones are absent. Families should carry an emergency letter with diagnosis, hospital instructions, and contact information.
Illness, Surgery, and Emergency Care
Catabolic stress is the main trigger for decompensation. Fever, gastroenteritis, repeated vomiting, poor intake, trauma, surgery, and prolonged labor can rapidly increase energy needs while reducing carbohydrate supply.
Sick-day plan
The metabolic center should provide age-specific instructions for frequent carbohydrate-containing fluids, feeding intervals, glucose monitoring when appropriate, and thresholds for hospital assessment. A child who cannot keep down emergency drinks, becomes unusually sleepy, or has persistent vomiting generally needs urgent evaluation.
Families should contact the metabolic service early rather than waiting for hypoglycemia. Home glucose can be useful but should not delay care, and a normal reading does not guarantee stability during ongoing poor intake.
Hospital treatment
Emergency treatment commonly includes intravenous dextrose at a rate sufficient to stop fat breakdown, correction of dehydration and electrolytes, and monitoring of glucose, liver function, acid-base status, ammonia, and other parameters. Insulin may occasionally be used under specialist supervision if high-dose glucose causes marked hyperglycemia; glucose should not simply be reduced in a catabolic patient without considering the metabolic goal.
Lipid emulsions and medium-chain triglyceride products require careful review. The emergency team should contact the person’s metabolic center because routine fasting or fluid protocols may be unsafe.
Surgery and procedures
Elective procedures require a preoperative plan that minimizes fasting. Scheduling first in the day, allowing clear carbohydrate fluids within anesthesia rules, starting intravenous glucose, and continuing support until normal intake resumes may be considered. The exact plan must be agreed upon by anesthesia, surgery, and metabolic teams.
Dental procedures, colonoscopy preparation, labor and delivery, and emergency surgery deserve the same attention. A short procedure can still create risk if the fasting instructions are long or postoperative nausea prevents eating.
When to seek immediate help
Repeated vomiting, refusal of feeds, unusual drowsiness, confusion, weakness, seizure, collapse, breathing difficulty, or inability to follow the sick-day plan warrants immediate emergency care. Caregivers should state that MCAD deficiency can cause life-threatening hypoketotic hypoglycemia and present the emergency letter.
Family Testing and Reproductive Risk
MCAD deficiency follows autosomal recessive inheritance. When both parents carry a pathogenic ACADM variant, each pregnancy has a 25% chance of an affected child, a 50% chance of a healthy carrier, and a 25% chance of a child who inherited neither familial variant.
These probabilities apply independently to every pregnancy and equally to all sexes. The parents of an affected child are usually carriers, but testing should confirm their variants and phase.
Siblings and newborn planning
An older sibling who has not been tested may need targeted testing, even if healthy. A future newborn sibling should have a plan established before birth. Rapid targeted testing, immediate feeding precautions, and biochemical testing may be arranged rather than relying solely on routine screening turnaround.
If symptoms develop, emergency treatment should begin regardless of pending results. A 25% recurrence risk is substantial enough to justify proactive neonatal coordination.
Extended family and partner testing
Siblings of a carrier parent may have a 50% chance of carrying that parent’s variant. Adult relatives can use a copy of the family laboratory report for targeted testing.
A known carrier’s reproductive partner should generally receive comprehensive ACADM analysis rather than testing only for the first person’s variant, because partners can carry different disease-causing variants. A negative partner test lowers but does not eliminate risk; residual risk depends on assay sensitivity and ancestry.
General partner carrier-screening principles apply, but the known familial variant must be explicitly included.
Prenatal and preimplantation testing
When both family variants are known, chorionic villus sampling or amniocentesis can determine fetal status. In vitro fertilization with PGT-M can test embryos before transfer. Testing can distinguish affected, carrier, and unaffected embryos or pregnancies, but laboratory setup requires advance planning.
Other options include donor gametes, adoption, or natural conception with an immediate newborn plan. Counseling should be balanced: MCAD deficiency can be life-threatening when unrecognized, yet outcomes are usually excellent when diagnosed early and fasting is managed successfully.
Questions for the Care Team
Consider asking:
- Is this an abnormal newborn screen, a biochemical diagnosis, or a confirmed molecular diagnosis?
- What were the C8 level, C8/C10 ratio, urine acylglycines, and carnitine results?
- Were two pathogenic ACADM variants found, and are they in trans?
- Does the test include sequencing and deletion/duplication analysis rather than c.985A>G alone?
- Is either finding a VUS or a variant associated with a milder biochemical phenotype?
- What is the maximum fasting interval for this child now, and when will it be revised?
- What foods, formulas, supplements, MCT products, or dieting approaches should be avoided?
- Is carnitine supplementation indicated and how will it be monitored?
- What exact symptoms and intake thresholds trigger the sick-day plan or hospital care?
- Does the emergency letter include dextrose and anesthesia instructions?
- How should school, travel, sports, dental work, surgery, pregnancy, and alcohol be handled?
- Which siblings and relatives need diagnostic or carrier testing?
- Should a reproductive partner receive full ACADM analysis?
- What prenatal or PGT-M options are available for the known family variants?
A useful ACADM result does more than name two variants. It links the molecular diagnosis to a written fasting schedule, an emergency plan that can be used anywhere, and targeted testing for relatives. That combination converts a potentially sudden fatal disorder into one that can usually be managed safely throughout life.
References
- Chang IJ, Lam C, Vockley J. Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. GeneReviews®, updated 2024. Expert clinical review.
- American College of Medical Genetics and Genomics. Newborn Screening ACT Sheets and Algorithms: Elevated C8 With Lesser Elevations of C6 and C10. Current clinical action resource, accessed 2026.
- Mason E, et al. Medium-Chain Acyl-CoA Dehydrogenase Deficiency. Endocrinology, Diabetes & Metabolism, 2023. Clinical review.
- Ibrahim SH, Bhandari J. Medium-Chain Acyl-CoA Dehydrogenase Deficiency. StatPearls, updated 2024. Clinical review.
- Anastasovska V, et al. Medium-Chain Acyl-CoA Dehydrogenase Deficiency in North Macedonia: Newborn Screening and Genetic Background. Journal of Pediatric Endocrinology and Metabolism, 2025. Population screening study.
- Freeman K, et al. A Series of Systematic Reviews and Roadmap for Evidence Generation in Medium-Chain Acyl-CoA Dehydrogenase Deficiency. Molecular Genetics and Metabolism, 2025. Systematic evidence review.
Disclaimer
This article provides general education and does not replace care from a metabolic specialist, geneticist, emergency clinician, or dietitian. Poor intake, repeated vomiting, unusual sleepiness, seizure, collapse, or inability to follow a sick-day plan in someone with MCAD deficiency requires urgent medical assessment. Fasting limits, supplements, diet, exercise, surgery, and emergency glucose treatment must follow an individualized metabolic protocol.
